Malignant lymphomas, or what do clinicians expect from pathologists?
Authors:
R. Pytlík
Authors‘ workplace:
1. interní klinika, Všeobecná fakultní nemocnice a 1. lékařská fakulta UK, Praha
Published in:
Čes.-slov. Patol., 47, 2011, No. 3, p. 94-95
Category:
Reviews Article
Overview
Although the diagnosis and treatment of malignant lymphomas achieved considerable progress, their expansion was more or less independent. Therefore, for quick, fast and clinical relevant diagnostic process is necessary that clinical physicians and pathologists work closely together. Clinicians have to give pathologists key informations, but pathologists have to be ready to ask for them when needed. This article gives some examples which illustrate these principles.
Keywords:
malignant lymphomas – pathology – clinics
Sources
1. Dave SS, Fu K, Wright GW, et al. Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006; 354: 2431–2442.
2. Thieblemont C, Nasser V, Felman P, et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004; 103: 2727–2737.
3. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010; 116: 2040–2045.
4. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. MabThera International Trial Group. Lancet Oncol 2006; 7: 379–91.
5. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732.
6. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579–4586.
7. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.
8. Bierman PJ. Natural history of follicular grade 3 non-Hodgkin’s lymphoma. Curr Opin Oncol 2007; 19: 433–437.
9. Meyer PN, Fu K, Greiner TC, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2010; 29: 200–207.
10. Swerdlow SH, Campo E, Harris NL, et al (eds). WHO classification of tumours of haematopoietic and lymphoid tissue. IARC, Lyon, 2008.
11. Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2008: 349–358.
12. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143: 1144–1150.
13. Sierra del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K. Primary CNS lymphoma in immunocompetent patients. Oncologist 2009; 14: 526–539.
14. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114: 2273–2279.
15. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569–1580.
16. Dreyling M, Hoster E, Bea S, et al. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network. Leuk Lymphoma 2010; 51: 1612–1622.
17. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.
Labels
Anatomical pathology Forensic medical examiner ToxicologyArticle was published in
Czecho-Slovak Pathology
2011 Issue 3
Most read in this issue
- Our experience with detection of JAK2 mutations in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative disorders
- Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview.
- Importance of cyclin D1 (and CD5) detection in the diagnosis of malignant lymphomas other than mantle cell lymphoma
- Glomus tumor of the stomach: A case report and review of the literature